MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2025-09-30, NAUT had -$10,582K decrease in cash & cash equivalents over the period. -$11,452K in free cash flow.

Cash Flow Overview

Change in Cash
-$10,582K
Free Cash flow
-$11,452K

Unit: Thousand (K) dollars (except for numbers of shares and EPS)
Cash Flow
2025-09-30
2025-06-30
Net loss
-13,574 -31,646
Stock-based compensation expense
1,496 3,877
Amortization of operating lease right-of-use assets
1,193 2,336
Depreciation
426 922
Amortization (accretion) of premium (discount) on securities, net
306 980
Prepaid expenses and other assets
11 -160
Accounts payable
-20 -51
Accrued expenses and other liabilities
942 390
Operating lease liabilities
-1,180 -2,295
Net cash used in operating activities
-11,034 -27,287
Proceeds from maturities of securities
28,363 45,878
Purchases of securities
27,493 11,278
Purchases of property and equipment
418 615
Net cash provided by investing activities
452 33,985
Proceeds from exercise of stock options
0 26
Proceeds from issuance of common stock under employee stock purchase plan
0 87
Net cash provided by financing activities
0 113
Net decrease in cash, cash equivalents and restricted cash
-10,582 6,811
Cash and cash equivalents at beginning of period
28,648 -
Cash and cash equivalents at end of period
24,877 -
Unit: Thousand (K) dollars

Time Plot

Show the time plot by selecting a row from the table.

Nautilus Biotechnology, Inc. (NAUT)

Nautilus Biotechnology, Inc. (NAUT)